CAR T cell therapy in primary brain tumors: current investigations and the future
YJ Lin, LA Mashouf, M Lim - Frontiers in immunology, 2022 - frontiersin.org
Chimeric antigen receptor T cells (CAR T cells) are engineered cells expressing a chimeric
antigen receptor (CAR) against a specific tumor antigen (TA) that allows for the identification …
antigen receptor (CAR) against a specific tumor antigen (TA) that allows for the identification …
The biology of ependymomas and emerging novel therapies
Ependymomas are rare central nervous system tumours that can arise in the brain's
supratentorial region or posterior fossa, or in the spinal cord. In 1924, Percival Bailey …
supratentorial region or posterior fossa, or in the spinal cord. In 1924, Percival Bailey …
Choroid plexus mast cells drive tumor-associated hydrocephalus
Y Li, C Di, S Song, Y Zhang, Y Lu, J Liao, B Lei… - Cell, 2023 - cell.com
Tumor-associated hydrocephalus (TAH) is a common and lethal complication of brain
metastases. Although other factors beyond mechanical obstructions have been suggested …
metastases. Although other factors beyond mechanical obstructions have been suggested …
Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q
LV Baroni, L Sundaresan, A Heled, H Coltin… - Neuro …, 2021 - academic.oup.com
Abstract Background Within PF-EPN-A, 1q gain is a marker of poor prognosis, however, it is
unclear if within PF-EPN-A additional cytogenetic events exist which can refine risk …
unclear if within PF-EPN-A additional cytogenetic events exist which can refine risk …
Advances in the molecular classification of pediatric brain tumors: a guide to the galaxy
C Cacciotti, A Fleming… - The Journal of pathology, 2020 - Wiley Online Library
Central nervous system (CNS) tumors are the most common solid tumor in pediatrics,
accounting for approximately 25% of all childhood cancers, and the second most common …
accounting for approximately 25% of all childhood cancers, and the second most common …
[HTML][HTML] Cognitive risk in survivors of pediatric brain tumors
A Oyefiade, I Paltin, CR De Luca, KK Hardy… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
Pediatric brain tumors (PBTs), the most common solid tumors of childhood, are a leading
cause of cancerrelated morbidity. Advancements in treatment have significantly improved …
cause of cancerrelated morbidity. Advancements in treatment have significantly improved …
Childhood malignant brain tumors: balancing the bench and bedside
C Thorbinson, JP Kilday - Cancers, 2021 - mdpi.com
Simple Summary Brain tumors remain the most common childhood solid tumors, accounting
for approximately 25% of all pediatric cancers. They also represent the most common cause …
for approximately 25% of all pediatric cancers. They also represent the most common cause …
Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial
SA Upadhyaya, GW Robinson, A Onar-Thomas… - Neuro …, 2019 - academic.oup.com
Background This report documents the clinical characteristics, molecular grouping, and
outcome of young children with ependymoma treated prospectively on a clinical trial …
outcome of young children with ependymoma treated prospectively on a clinical trial …
CAR T cell therapy for pediatric brain tumors
JD Patterson, JC Henson, RO Breese… - Frontiers in …, 2020 - frontiersin.org
Chimeric Antigen Receptor (CAR) T cell therapy has recently begun to be used for solid
tumors such as glioblastoma multiforme. Many children with pediatric malignant brain …
tumors such as glioblastoma multiforme. Many children with pediatric malignant brain …
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients
Accurate pathologic diagnoses and molecularly informed treatment decisions for a wide
variety of cancers depend on robust clinical molecular testing that uses genomic …
variety of cancers depend on robust clinical molecular testing that uses genomic …